BrendanJConnellMD

Oncology • Boston, MA

Genitourinary Oncology

Physician

Join to view full profile

Dr. Connell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Connell's full profile

Already have an account?

Office
41 Mall Road
Lahey Hospital and Medical Center
Boston, MA 01805
Phone+1 781-744-8400

Fax+1 781-744-5245

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Lahey ClinicChief Residency, Internal Medicine, 2014 - 2015
Lahey ClinicResidency, Internal Medicine, 2011 - 2014
Royal College of Surgeons IrelandClass of 2011
Harvard UniversityBA, 2005

Certifications & Licensure

MA State Medical License 2013 - 2026
NH State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2018 Jan 30
Active, not recruiting
Phase 1
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Start of enrollment: 2019 May 13
Recruiting
Phase 2
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate Start of enrollment: 2020 Mar 31
Active, not recruiting
Phase 3
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Start of enrollment: 2021 Mar 01
Active, not recruiting
Phase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Start of enrollment: 2021 Feb 25
Active, not recruiting
Phase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Start of enrollment: 2021 Apr 14
Active, not recruiting
Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Start of enrollment: 2021 Nov 03
Recruiting
Phase 3
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study Start of enrollment: 2022 Jun 30
Recruiting
Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Start of enrollment: 2024 Feb 02
Recruiting
Phase 2, Phase 3
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Start of enrollment: 2023 Dec 11
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Safety of sequential immune checkpoint inhibitors after prior immune therapy.
Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit
Journal of Cancer Research and Clinical Oncology. 2023-06-01
1 citations
Editorial Comment.
Brendan Connell, Esther Finney, Harras Zaid
The Journal of Urology. 2022-01-01
9 citations
Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype
Brendan Connell, Pavel Kopach, Wenying Ren, Raghav Joshi, Stephen P. Naber
Translational Andrology and Urology. 2020-07-22

Abstracts/Posters

Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial.
Brendan James Connell, Edmund Folefac, Clara Hwang, Christian Lawlor, Paul Mathew, GU ASCO 2021, 2/2021

Lectures

Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs).
2019 ASCO Annual Meeting - 6/1/2019

BrendanJConnellMD

Dr. Connell is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.